Characterisation of Patients with Severe Asthma in Primary and Secondary Care Settings in Europe reported to be eligible for biological therapy

Trial Identifier: D3250R00039
Sponsor: AstraZeneca
NCTID:: NCT03629782
Start Date: April 2018
Primary Completion Date: July 2020
Study Completion Date: July 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations